文献速递重症综合管理与镇静镇痛

重症监护病房谵妄患者使用抗精神病药物与QTc间期的关系:一项随机临床试验的二次分析

Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-01-02
一句话结论在基线QTc正常且延长风险因素少的ICU谵妄患者中,氟哌啶醇或齐拉西酮未显著延长次日QTc间期,每日QTc监测价值可能有限。

该研究为一项随机临床试验的预设二次分析,纳入美国16个中心内科/外科ICU的566例谵妄成人患者,基线QTc<550 ms,1:1:1随机接受静脉氟哌啶醇、齐拉西酮或生理盐水安慰剂,每日两次至谵妄缓解、ICU出院或14天。结果显示,与安慰剂相比,氟哌啶醇(OR 0.95;95%CI 0.66-1.37;P=.78)和齐拉西酮(OR 1.09;95%CI 0.75-1.57;P=.78)均未显著改变次日QTc间期,性别无显著交互作用(交互P=.41)。发生2例非致命性尖端扭转型室速,均在氟哌啶醇组,但均与研究药物给药无关。作者认为,对基线QTc正常且延长风险因素少的ICU谵妄患者,抗精神病药物使用期间每日QTc监测价值可能有限。

要点

  • 在基线QTc<550 ms的ICU谵妄患者中,氟哌啶醇组次日QTc间期与安慰剂组无显著差异(OR 0.95;95%CI 0.66-1.37;P=.78)。
  • 齐拉西酮组次日QTc间期与安慰剂组亦无显著差异(OR 1.09;95%CI 0.75-1.57;P=.78)。
  • 性别对抗精神病药物与次日QTc间期的关系无显著修饰作用(交互P=.41)。
  • 共发生2例非致命性尖端扭转型室速,均在氟哌啶醇组,但均与研究药物给药无关。
  • 作者认为,对基线QTc正常且QTc延长风险因素少的ICU谵妄患者,每日QTc监测价值可能有限。

适用人群与场景

  • 美国16个中心内科/外科ICU的成人谵妄患者,基线QTc间期<550 ms。
  • 研究时间为2011年12月至2017年8月。

诊断标准与关键阈值

  • 基线QTc间期<550 ms为纳入标准之一。

处置流程与药物剂量

  • 患者按1:1:1随机接受静脉氟哌啶醇、齐拉西酮或生理盐水安慰剂,每日两次,直至谵妄缓解、ICU出院或14天。
  • 基线时及每次后续研究药物给药前分别用12导联心电图和遥测测量QTc。

红旗征与不能漏的情况

  • 研究期间发生2例非致命性尖端扭转型室速,均在氟哌啶醇组,但均与研究药物给药无关。

研究设计与关键结果

  • 研究类型为随机临床试验的预设二次分析,共纳入566例患者,随机分为氟哌啶醇组(n=192)、齐拉西酮组(n=190)和安慰剂组(n=184)。
  • 中位年龄60.1岁(IQR 51.4-68.7),男性323例(57%)。
  • 基线中位QTc:氟哌啶醇组458.0 ms(IQR 432.0-479.0),齐拉西酮组451.0 ms(IQR 424.0-472.0),安慰剂组452.0 ms(IQR 432.0-472.0)。
  • 第1天至第2天中位QTc变化:氟哌啶醇组-1.0 ms(IQR -28.0至15.0),齐拉西酮组0 ms(IQR -23.0至20.0),安慰剂组-3.5 ms(IQR -24.8至17.0)。
  • 与安慰剂相比,氟哌啶醇与次日QTc间期无显著关联(OR 0.95;95%CI 0.66-1.37;P=.78),齐拉西酮亦无显著关联(OR 1.09;95%CI 0.75-1.57;P=.78)。
  • 性别无显著交互作用(交互P=.41)。

证据类型、等级与局限

  • 证据类型:随机临床试验的预设二次分析。
  • 所有分析基于意向治疗原则。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对基线QTc正常且QTc延长风险因素少的ICU谵妄患者,抗精神病药物使用期间每日QTc监测价值可能有限。

指南或共识出处

  • ClinicalTrials.gov注册号NCT01211522。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Antipsychotic medications, often prescribed for delirium in intensive care units (ICUs), may contribute to QTc interval prolongation.

OBJECTIVE: To determine whether antipsychotics increase the QTc interval in patients with delirium in the ICU.

DESIGN, SETTING, AND PARTICIPANTS: An a priori analysis of a randomized clinical trial in medical/surgical ICUs within 16 centers across the US was conducted. Participants included adults with delirium in the ICU with baseline QTc interval less than 550 ms. The study was conducted from December 2011 to August 2017. Data analysis was performed from April 25 to August 18, 2021.

INTERVENTIONS: Patients were randomized 1:1:1 to intravenous haloperidol, ziprasidone, or saline placebo administered twice daily until resolution of delirium, ICU discharge, or 14 days.

MAIN OUTCOMES AND MEASURES: Twelve-lead electrocardiograms were used to measure baseline QTc before study drug initiation and telemetry was used to measure QTc before each subsequent dose of study drug. Unadjusted day-to-day changes in QTc were calculated and multivariable proportional odds regression was used to estimate the effects of antipsychotics vs placebo on next-day maximum QTc interval, adjusting for prespecified baseline covariates and potential interactions with sex. Safety end points, including the occurrence of torsade de pointes, were evaluated. All analyses were conducted based on the intention to treat principle.

RESULTS: A total of 566 patients were randomized to haloperidol (n = 192), ziprasidone (n = 190), or placebo (n = 184). Median age was 60.1 (IQR, 51.4-68.7) years; 323 were men (57%). Baseline median QTc intervals across the groups were similar: haloperidol, 458.0 (IQR, 432.0-479.0) ms; ziprasidone, 451.0 (IQR, 424.0-472.0) ms; and placebo, 452.0 (IQR, 432.0-472.0) ms. From day 1 to day 2, median QTc changed minimally: haloperidol, -1.0 (IQR, -28.0 to 15.0) ms; ziprasidone, 0 (IQR, -23.0 to 20.0) ms; and placebo, -3.5 (IQR, -24.8 to 17.0) ms. Compared with placebo, neither haloperidol (odds ratio [OR], 0.95; 95% CI, 0.66-1.37; P = .78) nor ziprasidone (OR, 1.09; 95% CI, 0.75-1.57; P = .78) was associated with next-day QTc intervals. Effects were not significantly modified by sex (P = .41 for interaction). There were 2 occurrences of nonfatal torsade de pointes, both in the haloperidol group. Neither was associated with study drug administration.

CONCLUSIONS AND RELEVANCE: The findings of this trial suggest that daily QTc interval monitoring during antipsychotic use may have limited value in patients in the ICU with normal baseline QTc and few risk factors for QTc prolongation.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01211522.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Stollings JL, Boncyk CS, Birdrow CI, et al. Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38252439. doi:10.1001/jamanetworkopen.2023.52034

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。